EBs have historically been described as metabolically dormant. A cell-free (axenic) culture system was developed, which showed high levels of metabolic and biosynthetic activity from both EBs and RBs, although the requirements differed for each. EBs preferentially used glucose-6-phosphate as an energy source, whereas RBs required ATP. Both developmental forms showed increased activity when incubated under microaerobic conditions. Incorporation of isotopically labeled amino acids into proteins from both developmental forms indicated unique expression profiles, which were confirmed by genome-wide transcriptional analysis.
Garenoxacin showed the most potent chlamydial activity against Chlamydia trachomatis D/UW-3/Cx among three tested quinolones and azithromycin.
Solithromycin is a next-generation oral and intravenous fluoroketolide. Solithromycin is the first fluoroketolide with a number of attributes that may provide clinically important advantages over several comparator products: Eight to 16 times more potent than azithromycin and is active against organisms that have become resistant to azithromycin Potent in vitro activity against all important respiratory pathogens, including pneumococci, beta-hemolytic streptococci, staphylococci, Hemophilus, Legionella, Mycoplasma, Moraxella and Chlamydophila
The chemists of the Duke University designed a molecule that could block the CPAF activity inside of human cells.
They found that when CPAF was blocked over time by their designed molecule, the protective home that the bacteria make for themselves within the infected cells degraded, and CPAF no longer could degrade the proteins in the cell that would normally mount an immune response to the infection.
When CPAF is inhibited, the infected human cells effectively commit suicide. When the infected human cell dies, so does Chlamydia, and this ends the infection.